

Artificial Intelligence-Based Systems for Cancer Diagnosis: Trends and Future Prospects

DAMILOLA OSAMIKA¹, BAMIDELE SAMUEL ADELUSI², MARIATHERESA CHINYEAKA
KELVIN-AGWU³, ASHIATA YETUNDE MUSTAPHA⁴, NURA IKHALEA⁵

¹Department of Environmental Health, Margaret Mosunmola College of Health Science and Technology,
Nigeria

²Software Engineer, SigmaXplus Solutions LLC, USA

³Independent Researcher, Lagos Nigeria

⁴Kwara State Ministry of Health, Nigeria

⁵Independent Researcher, Texas, USA

Abstract- Cancer remains a leading cause of morbidity and mortality worldwide, necessitating advancements in early detection and accurate diagnosis to improve patient outcomes. Artificial Intelligence (AI)-based systems have emerged as transformative tools in oncology, leveraging machine learning (ML) and deep learning (DL) algorithms to enhance diagnostic accuracy, reduce human error, and facilitate personalized treatment strategies. This systematic review explores current trends and future prospects in AI-driven cancer diagnosis, highlighting key technologies, data sources, performance metrics, challenges, and innovations. AI technologies, including convolutional neural networks (CNNs), transformer-based models, and radiomics, have demonstrated remarkable efficacy in analyzing medical imaging modalities such as MRI, CT scans, and histopathological slides. Additionally, AI models integrate multi-omics data, electronic health records (EHRs), and real-time biosensor data to improve diagnostic precision. Performance evaluation metrics, including accuracy, sensitivity, specificity, and AUC-ROC, play a crucial role in validating AI models against traditional diagnostic methods. Despite its potential, AI implementation in cancer diagnosis faces challenges such as data standardization, model interpretability, and regulatory compliance (HIPAA, GDPR). Bias in AI models and the need for explainable AI remain critical concerns for clinical adoption. However, advancements in federated learning, predictive analytics, and AI-powered precision oncology are expected to address these limitations, fostering trust and integration into healthcare workflows. Future

research should focus on enhancing AI-human collaboration, ensuring data security, and refining deep learning architectures for greater diagnostic efficiency. As AI continues to evolve, it holds immense promise in revolutionizing cancer diagnostics, ultimately improving early detection, reducing healthcare costs, and enabling more effective treatment planning. This review provides a comprehensive analysis of AI-driven cancer diagnostic systems, emphasizing their transformative role and the future trajectory of AI applications in oncology.

Indexed Terms- Artificial intelligence, Cancer diagnosis, AI-powered precision oncology, Review

I. INTRODUCTION

Cancer remains one of the most pressing global health challenges, contributing to significant morbidity and mortality worldwide (Gbadegesin *et al.*, 2022). According to the World Health Organization (WHO), cancer is responsible for nearly 10 million deaths annually, with projections indicating a steady increase in cases due to aging populations, environmental factors, and lifestyle changes. The economic burden of cancer is also substantial, affecting healthcare systems, economies, and families across the globe. The complexity of cancer arises from its diverse subtypes, genetic variations, and unpredictable progression, making accurate detection and timely intervention critical for improving patient outcomes (Bristol-Alagbariya *et al.*, 2022; Adewoyin, 2022).

Early and accurate diagnosis is a cornerstone of effective cancer treatment and management. Detecting cancer in its initial stages significantly increases survival rates and improves the efficacy of therapeutic interventions (Ozobur *et al.*, 2022). Traditional diagnostic methods, such as histopathology, radiology, and biomarker analysis, rely on expert interpretation, which can be time-consuming and prone to human error. Moreover, disparities in healthcare access and variability in diagnostic accuracy pose additional challenges (Matthew *et al.*, 2021). The need for more efficient, reliable, and scalable diagnostic solutions has led to the integration of Artificial Intelligence (AI) into oncology.

AI has revolutionized cancer detection and diagnosis by enhancing the accuracy, speed, and efficiency of existing methodologies. Machine learning (ML) and deep learning (DL) algorithms have demonstrated remarkable potential in analyzing complex medical data, identifying patterns, and improving diagnostic precision (Ige *et al.*, 2022; Ajayi and Akerele, 2022). AI-powered systems are now capable of processing medical images, genomic data, and clinical records, thereby assisting healthcare professionals in making data-driven decisions. Convolutional neural networks (CNNs), for instance, have achieved expert-level performance in identifying abnormalities in radiological images, while transformer-based models are advancing pathology and genomic analysis. These technologies help reduce diagnostic errors, improve workflow efficiency, and facilitate personalized treatment strategies (Collins *et al.*, 2022).

The objective of this, is to explore the current trends and future prospects of AI-based systems in cancer diagnosis. This includes an in-depth review of AI technologies utilized in oncology, their integration with various diagnostic modalities, and their impact on early detection. Additionally, this examines challenges related to data quality, model interpretability, regulatory compliance, and ethical concerns. Future directions in AI-driven cancer diagnostics, including advancements in federated learning, multi-modal AI models, and real-time predictive analytics, will also be discussed (Hamza *et al.*, 2022). By analyzing existing literature and real-world implementations, this aims to provide a comprehensive overview of how AI is transforming cancer diagnosis and shaping the future

of oncology. Understanding these advancements will aid researchers, clinicians, and policymakers in adopting AI-driven solutions that enhance diagnostic accuracy, optimize healthcare delivery, and ultimately improve patient outcomes.

II. METHODOLOGY

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology was followed to ensure a structured and transparent approach to reviewing the literature on artificial intelligence-based systems for cancer diagnosis. A systematic search was conducted across multiple electronic databases, including PubMed, IEEE Xplore, Scopus, and Google Scholar, to identify relevant peer-reviewed articles published in the last decade. The search strategy incorporated a combination of keywords and Boolean operators, such as "Artificial Intelligence," "Machine Learning," "Deep Learning," "Cancer Diagnosis," "Medical Imaging," and "Predictive Analytics."

Eligibility criteria were established to include studies that specifically examined AI-driven approaches for cancer detection, classification, and diagnosis. Articles that focused on model development, performance evaluation, and clinical applications were considered, while studies that lacked empirical validation, review articles without original data, and non-English publications were excluded. The initial search retrieved a large set of studies, which were then screened for relevance based on titles and abstracts. Duplicates were removed, and full-text articles were assessed against the inclusion and exclusion criteria.

Data extraction was performed using a standardized approach, capturing key information such as study objectives, AI methodologies used, dataset characteristics, performance metrics, and clinical validation outcomes. A PRISMA flowchart was constructed to illustrate the study selection process, detailing the number of records identified, screened, excluded, and included in the final analysis. The synthesis of the selected studies focused on comparing different AI techniques, highlighting advancements in model accuracy, interpretability, and integration with clinical workflows.

By adhering to the PRISMA framework, this systematic review provides a comprehensive and unbiased evaluation of the role of artificial intelligence in cancer diagnosis, identifying key trends, challenges, and future research directions.

2.1 AI Technologies in Cancer Diagnosis

Artificial Intelligence (AI) has revolutionized cancer diagnosis by enhancing the accuracy, efficiency, and speed of detection. With advancements in machine learning (ML) and deep learning (DL), AI-driven systems are now capable of analyzing complex medical data, from imaging to genomic profiling, enabling early detection and personalized treatment plans (Bristol-Alagbariya *et al.*, 2022). This explores the role of AI in cancer diagnosis, focusing on ML and DL approaches, AI applications in medical imaging, and AI-driven histopathology and genomic analysis.

Machine learning techniques, particularly supervised and unsupervised learning, have significantly contributed to cancer detection. In supervised learning, AI models are trained using labeled datasets where input variables (such as medical images or genomic data) are mapped to known cancerous or non-cancerous outcomes (Charles *et al.*, 2022). This approach is widely used in diagnostic tools, where models learn to differentiate malignant from benign tumors. Unsupervised learning, on the other hand, enables AI to detect patterns in unlabeled data, aiding in patient stratification and the discovery of novel cancer subtypes. Among deep learning techniques, Convolutional neural networks (CNNs) have gained prominence in medical imaging analysis. CNNs process large amounts of imaging data, identifying minute details in radiological scans that may be imperceptible to the human eye (Jahun *et al.*, 2021; Bidemi *et al.*, 2021). These networks extract hierarchical features from images, allowing for accurate tumor classification, segmentation, and prediction of cancer progression.

Another emerging AI technique is Transformer-based models, which have demonstrated remarkable performance in histopathological image interpretation (Adepoju *et al.*, 2022). These models use self-attention mechanisms to analyze large pathology images, capturing intricate tissue patterns that indicate malignancy. Transformer-based architectures, such as

Vision Transformers (ViTs), outperform traditional CNNs in tasks like tumor grading and tissue classification, making them a promising tool in digital pathology. Medical imaging plays a crucial role in cancer diagnosis, and AI-driven technologies have significantly enhanced imaging-based detection methods. Radiomics, a field that extracts quantitative features from medical images, is now integrated with AI-powered radiology to improve cancer detection (Dirlikov *et al.*, 2021). AI algorithms analyze radiomic features from MRI, CT scans, and PET scans, identifying tumor heterogeneity and predicting treatment responses. In MRI and CT scans, AI applications have streamlined cancer detection by automating image segmentation and lesion characterization (Ige *et al.*, 2022). AI models trained on vast imaging datasets can distinguish between normal and abnormal tissues, reducing false positives and improving diagnostic confidence. In mammography, AI-powered tools assist radiologists in identifying early-stage breast cancer, increasing the accuracy of screening programs. Positron emission tomography (PET) scans also benefit from AI advancements, where deep learning models improve lesion detection and metabolic activity assessment. AI-based segmentation techniques help in delineating tumor boundaries with high precision, aiding oncologists in treatment planning (Atta *et al.*, 2021; Adepoju *et al.*, 2022). These innovations reduce the workload on radiologists while ensuring consistent and reproducible cancer diagnoses.

Histopathology, the microscopic examination of tissue samples, is critical for cancer diagnosis. AI-driven digital pathology has transformed histopathological analysis by automating slide scanning, feature extraction, and abnormality detection (Adepoju *et al.*, 2022). Deep learning models, particularly CNNs and Transformers, analyze whole-slide images to classify cancer grades, detect mitotic figures, and predict patient prognosis. Digital pathology powered by AI reduces diagnostic variability among pathologists and enables high-throughput cancer screening. AI is also reshaping genomic analysis, paving the way for precision oncology. AI-driven models analyze genomic sequencing data to identify cancer-associated mutations, guiding personalized treatment strategies. By integrating multi-omics data (including DNA, RNA, and proteomic profiles), AI enhances biomarker

discovery and patient-specific therapeutic recommendations. Machine learning algorithms predict tumor behavior based on genetic signatures, enabling oncologists to select targeted therapies with higher efficacy.

AI technologies have significantly advanced cancer diagnosis through machine learning, deep learning, medical imaging analysis, and genomic profiling (Akinade *et al.*, 2022). From CNNs improving radiological assessments to Transformer-based models enhancing histopathological interpretations, AI is reshaping cancer diagnostics with unprecedented accuracy and efficiency. The integration of AI with radiomics, digital pathology, and precision medicine holds great potential for early detection and personalized treatment. Continued research and clinical validation will further refine AI-driven cancer diagnosis, ultimately improving patient outcomes and revolutionizing oncology care (Ajayi and Akerele, 2022).

2.2 Data Sources and Integration for AI-Based Cancer Diagnosis

Artificial Intelligence (AI) has emerged as a transformative force in cancer diagnosis, leveraging diverse data sources to enhance predictive accuracy and early detection (Egbonu *et al.*, 2022). The integration of AI with Electronic Health Records (EHRs), multi-omics data, wearable devices, and telemedicine has revolutionized oncology by providing comprehensive patient insights as shown in figure 1. This explores the significance of these data sources and their integration into AI-driven cancer diagnostic systems.




Figure 1: Data Sources and Integration for AI-Based Cancer Diagnosis

Electronic health records (EHRs) serve as a rich repository of patient health information, including medical history, laboratory test results, imaging reports, and treatment records (Adegoke *et al.*, 2022). AI models trained on EHR data can analyze patient demographics, symptoms, and risk factors to detect patterns indicative of cancer development. Machine learning algorithms utilize structured clinical data to generate risk scores, aiding in early diagnosis and prognosis prediction.

Natural language processing (NLP) techniques further enhance AI's ability to extract meaningful information from unstructured clinical notes, pathology reports, and radiology descriptions (Opia *et al.*, 2022). By standardizing and integrating EHR data, AI systems can offer decision-support tools for oncologists, helping them identify high-risk patients and recommend personalized treatment strategies. However, challenges such as missing data, interoperability issues, and privacy concerns must be addressed to maximize the potential of EHR-driven AI models.

The advent of multi-omics research has provided deeper insights into cancer pathophysiology. AI-driven models integrate genomic, proteomic, and metabolomic data to uncover molecular signatures associated with different cancer types. Genomics, AI analyzes next-generation sequencing (NGS) data to identify genetic mutations, copy number variations, and chromosomal abnormalities linked to oncogenesis (Matthew *et al.*, 2022). This allows for the detection of cancer susceptibility genes and the development of targeted therapies. Proteomics, machine learning algorithms process protein expression data to identify cancer-specific biomarkers, aiding in early diagnosis and drug discovery. Deep learning models analyze mass spectrometry data to detect aberrant protein patterns that indicate tumor progression. Metabolomics. AI-driven metabolomic analysis assesses metabolic alterations in cancer patients. By examining metabolite profiles in blood, urine, and tissue samples, AI models can differentiate between malignant and benign conditions, facilitating non-invasive cancer screening. Integrating multi-omics data with AI not only enhances diagnostic accuracy but also enables precision oncology, where treatment plans are tailored based on a patient's unique

molecular profile (Adepoju *et al.*, 2022). However, challenges such as data standardization, computational complexity, and ethical concerns regarding genetic data privacy remain key hurdles.

Wearable technologies and biosensors provide continuous, real-time monitoring of physiological and biochemical parameters, offering a proactive approach to cancer detection. AI-driven analysis of wearable device data allows for early identification of subtle health changes that may indicate malignancies (Govender *et al.*, 2022). Changes in autonomic nervous system activity can serve as early indicators of cancer-related fatigue or metabolic alterations. AI models analyze fluctuations in glucose metabolism and oxygen levels, which may signal tumor growth. Advanced biosensors detect specific cancer biomarkers in blood samples, facilitating non-invasive liquid biopsies for early detection. AI-powered wearable devices offer significant advantages, including remote patient monitoring, early disease detection, and reduced dependence on hospital visits. However, ensuring the reliability, accuracy, and security of real-time data remains a major challenge for widespread clinical adoption.

Telemedicine has emerged as a crucial component of modern healthcare, especially in oncology, where timely diagnosis and follow-up care are essential (Adepoju *et al.*, 2022). AI-powered telemedicine platforms enable remote consultations, second opinions, and diagnostic support, bridging the gap between patients and oncologists. Patients can upload diagnostic scans (e.g., mammograms, CT scans) to cloud-based AI systems that analyze images for cancerous lesions and provide instant feedback to clinicians. Digital pathology platforms equipped with AI tools assist pathologists in analyzing tissue samples remotely, reducing diagnostic turnaround time. AI-powered chatbots offer symptom assessment and triage services, directing patients to appropriate oncological care. By integrating AI with telemedicine, healthcare systems can expand cancer diagnostic services to remote and underserved populations (Collins *et al.*, 2022). However, challenges such as data security, regulatory compliance, and the need for high-quality telecommunication infrastructure must be addressed. The integration of diverse data sources, including EHRs, multi-omics data, wearable devices,

and telemedicine, has revolutionized AI-based cancer diagnosis. By leveraging these data streams, AI-driven systems enhance diagnostic accuracy, enable personalized treatment, and improve patient outcomes. Despite challenges related to data quality, privacy, and computational demands, ongoing advancements in AI and data integration will continue to shape the future of oncology, making cancer detection more accessible and efficient worldwide (Tomassoni *et al.*, 2013; Adelodun *et al.*, 2018).

2.3 Performance Evaluation of AI Models in Cancer Detection

Artificial Intelligence (AI) has revolutionized cancer detection by providing more accurate, efficient, and scalable diagnostic solutions (Matthew *et al.*, 2021). However, evaluating the performance of AI models is critical to ensuring their reliability and clinical applicability. Various metrics and validation techniques are employed to assess AI models, often comparing them to traditional diagnostic methods. This explores key performance metrics, benchmarking against conventional techniques, and validation strategies for AI-based cancer detection.

Evaluating AI models in cancer detection requires a robust set of performance metrics that account for accuracy, reliability, and clinical utility. Accuracy, the proportion of correctly classified cancer cases (both malignant and benign) out of the total cases (Jahun *et al.*, 2021). While accuracy is a useful metric, it can be misleading when dealing with imbalanced datasets, where one class (e.g., benign cases) dominates. Precision (Positive Predictive Value), the proportion of true positive cancer cases among all cases classified as positive by the AI model. High precision indicates a low false positive rate, reducing unnecessary biopsies and treatments. Recall (Sensitivity), the proportion of actual cancer cases that the AI model correctly identifies. High recall ensures that fewer cancer cases go undetected, which is crucial for early-stage detection. F1-score, the harmonic means of precision and recall, balancing the trade-off between false positives and false negatives. It is particularly useful when data is imbalanced, ensuring both specificity and sensitivity are accounted for.

Area under the curve – receiver operating characteristic (AUC-ROC) measures the ability of an

AI model to distinguish between cancerous and non-cancerous cases at various threshold levels. A high AUC value (close to 1) indicates that the model effectively differentiates between malignant and benign cases. This metric is crucial for comparing different AI models and optimizing classification thresholds in clinical settings. Sensitivity (True Positive Rate), measures how effectively the model identifies cancer cases (Austin-Gabriel *et al.*, 2021). A highly sensitive model minimizes false negatives, ensuring that most cancer cases are detected early. Specificity (True Negative Rate), determines how well the model classifies non-cancerous cases. High specificity is important to prevent overdiagnosis and unnecessary treatments. Achieving an optimal balance between sensitivity and specificity is crucial in AI-based cancer detection, as missing a cancer diagnosis (false negative) can be life-threatening, while overdiagnosis (false positive) can lead to unnecessary psychological distress and medical interventions.

AI models must demonstrate superior or at least comparable performance to traditional cancer diagnostic methods before clinical adoption (Hussain *et al.*, 2021). Key comparisons include; AI models, especially deep learning-based algorithms, have shown comparable or even superior accuracy in detecting tumors in mammography, MRI, and CT scans. Studies have reported that AI can match radiologists in breast cancer detection while significantly reducing reading time. AI-driven digital pathology enhances tissue sample evaluation, increasing diagnostic consistency and efficiency. AI-powered models can process vast histopathological datasets more rapidly than human pathologists while reducing observer variability. AI enhances genomic and proteomic data analysis, providing personalized cancer risk assessments. Unlike traditional biomarker-based methods that rely on predefined markers, AI can uncover novel biomarker patterns using multi-omics integration. AI integration in large-scale cancer screening programs has demonstrated potential in improving early cancer detection, especially in lung, breast, and colorectal cancers (Adepoju *et al.*, 2022). These AI-assisted screenings often outperform traditional statistical models in predicting cancer risk. While AI models offer numerous advantages, they must be rigorously validated and subjected to regulatory scrutiny before clinical implementation.




Figure 2: Model Validation Techniques

To ensure generalizability and robustness, AI models must undergo thorough validation before deployment. The most widely used validation techniques include as shown in figure 2 above; K-fold cross-validation, the dataset is split into K subsets, where the model is trained on K-1 folds and tested on the remaining fold. This process is repeated K times, ensuring that each sample is used for testing exactly once. This technique mitigates overfitting and improves model reliability. Stratified cross-validation, Maintains the same class distribution across training and testing sets, preventing bias in imbalanced datasets common in oncology (Ike *et al.*, 2021).

While cross-validation ensures internal consistency, external validation is essential to assess an AI model's performance on independent datasets from different institutions or geographic regions. AI models validated on diverse, real-world datasets demonstrate better generalizability and clinical applicability. Multi-center validation, AI models trained on data from one hospital may not generalize well to another. Multi-center validation tests the model on datasets from different hospitals to ensure robustness (Tomassoni *et al.*, 2018). Prospective validation, AI models should be tested on real-time, prospective patient data to evaluate performance in a clinical workflow. AI models should be benchmarked against established cancer risk prediction models like the Gail Model for breast cancer or the Lung-RADS system for lung cancer screening to demonstrate added value. The performance evaluation of AI models in cancer detection is crucial for their clinical adoption and reliability. Metrics such as accuracy, precision, recall, F1-score, AUC-ROC, sensitivity, and specificity provide quantitative measures of model effectiveness. Benchmarking AI models against radiologists, histopathologists, and traditional biomarker-based

methods ensures their clinical relevance. Furthermore, rigorous cross-validation and external validation strategies enhance model generalizability and robustness. As AI continues to evolve, improving performance evaluation methods will be essential for integrating AI-driven cancer diagnostics into routine clinical practice.

2.4. Challenges and Limitations of AI-Based Cancer Diagnosis

Artificial intelligence (AI) has significantly transformed cancer diagnosis, offering improvements in speed, accuracy, and efficiency (Kuo *et al.*, 2019). However, despite its potential, AI-based cancer diagnosis faces numerous challenges and limitations that hinder its widespread clinical adoption. Key concerns include data quality and standardization, model interpretability and trustworthiness, ethical and regulatory compliance, bias and fairness, and integration challenges with existing healthcare infrastructure.

One of the primary challenges in AI-based cancer diagnosis is the availability and quality of data. AI models require vast amounts of high-quality, well-annotated data to function effectively. However, medical datasets are often fragmented, incomplete, or inconsistent, leading to reduced model reliability. Cancer datasets frequently suffer from class imbalance, where certain cancer types are overrepresented while others are underrepresented (Elujide *et al.*, 2021). This imbalance can lead to AI models being biased toward more common cancer types, reducing their ability to detect rare cancers accurately. Many clinical datasets contain missing values, particularly in electronic health records (EHRs). AI models trained on incomplete data may fail to generalize well, leading to poor diagnostic accuracy. Different healthcare institutions use varied imaging protocols, data formats, and labeling methods, making it difficult to train AI models on heterogeneous datasets. The lack of universal data-sharing standards further complicates model development and validation across multiple institutions (Olamijuwon, 2020). Efforts to improve data harmonization, annotation consistency, and standardization are essential to enhancing AI's effectiveness in cancer diagnosis.

AI models, especially deep learning approaches like Convolutional neural networks (CNNs) and transformer-based models, often function as "black boxes," meaning their decision-making process is not easily interpretable. This lack of transparency limits clinical trust and adoption. Clinicians require clear justifications for AI-driven diagnoses (Oyedokun, 2019). If an AI model detects cancer but cannot explain its reasoning, physicians may hesitate to rely on its recommendations. Healthcare regulatory bodies require AI models to be explainable and auditable before they can be used in clinical practice. Black-box AI models struggle to meet these requirements, delaying their approval. AI models may produce high-confidence yet incorrect predictions, leading to potential misdiagnoses. Without proper interpretability mechanisms, it becomes difficult to correct such errors. Developing explainable AI (XAI) methods, such as saliency maps, attention mechanisms, and feature importance analysis, can help improve trust in AI-driven cancer diagnosis.

The integration of AI into cancer diagnostics raises serious ethical and legal challenges, particularly concerning patient privacy, data security, and informed consent. Key regulations such as the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. and the General Data Protection Regulation (GDPR) in Europe impose strict guidelines on the handling of medical data. AI models require access to vast amounts of patient data, raising concerns about unauthorized access, data breaches, and re-identification risks (Oladosu *et al.*, 2021). Ensuring compliance with HIPAA and GDPR regulations is essential to protecting patient confidentiality. Patients must be fully informed about how their medical data is used for AI training. Many AI applications currently lack transparency in data usage policies. If an AI model makes an incorrect diagnosis leading to patient harm, determining legal liability remains a complex issue. Regulatory frameworks for AI accountability in healthcare are still evolving. To address these concerns, secure AI architectures, federated learning, and differential privacy techniques must be implemented to ensure ethical AI deployment.

AI models can inherit and amplify biases present in training datasets, leading to disparities in cancer diagnosis across different populations. Bias in AI-

driven cancer diagnosis arises from; Many AI models are trained on Western-centric datasets, which may not generalize well to underrepresented ethnic groups (Agho *et al.*, 2021). AI models may perform poorly in low-resource settings where access to high-quality imaging and healthcare data is limited. If historical diagnostic data reflects past medical biases, AI models may reinforce existing disparities rather than correcting them. To improve fairness, AI models must undergo bias auditing, fairness testing, and inclusion of diverse datasets covering multiple ethnicities, genders, and socioeconomic backgrounds (Nwaozumudoh *et al.*, 2021).

Deploying AI-based cancer diagnostic tools within current healthcare systems presents significant integration challenges. Many hospitals and clinics use legacy EHR systems that are not optimized for AI integration. Standardizing EHR-AI interfaces is necessary for seamless interoperability. AI-driven cancer diagnosis requires high computational power, which may not be available in smaller hospitals or low-resource settings. AI tools must be designed to complement rather than disrupt existing clinical workflows. Many radiologists and oncologists remain skeptical about AI replacing traditional diagnostic methods. AI should act as a decision-support tool rather than a replacement for human expertise (Odio *et al.*, 2021). Encouraging clinician-AI collaboration through hybrid diagnostic models is key to successful implementation. Healthcare institutions must invest in AI infrastructure, clinician training, and robust validation frameworks to ensure smooth AI adoption.

While AI holds great promise in enhancing cancer diagnosis, several challenges and limitations must be addressed before widespread clinical adoption. Data quality, model interpretability, ethical and regulatory compliance, bias mitigation, and healthcare integration remain significant hurdles. Overcoming these challenges requires improved data standardization, explainable AI methods, robust privacy frameworks, fairness auditing, and seamless EHR integration (Dienagha *et al.*, 2021). By addressing these limitations, AI-based cancer diagnostics can achieve greater accuracy, equity, and trustworthiness, ultimately improving early cancer detection and patient outcomes.

2.5 Future Directions and Innovations in AI for Cancer Diagnosis

Artificial intelligence (AI) has revolutionized cancer diagnosis, enabling early detection, improved accuracy, and personalized treatment strategies (Oluokun, 2021). As AI continues to evolve, emerging advancements promise to further enhance its capabilities in oncology. Key future directions include the development of explainable AI, AI-powered precision oncology, privacy-preserving federated learning, predictive analytics, and AI-human collaboration as shown in figure 3. These innovations aim to overcome existing limitations while improving diagnostic efficiency and clinical outcomes. Deep learning has significantly improved cancer diagnosis, particularly in medical imaging, histopathology, and genomic analysis. However, a critical challenge remains: the “black-box” nature of deep learning models, which limits their interpretability and trust in clinical settings. Future research focuses on explainable AI (XAI) to enhance transparency and trustworthiness. Techniques like Grad-CAM (Gradient-weighted Class Activation Mapping) highlight key regions in medical images that contribute to an AI model’s decision, making it easier for clinicians to interpret AI-driven diagnoses. Hybrid models, such as attention-based transformers and case-based reasoning models, aim to provide human-like explanations for AI decisions. (Adewoyin, 2021) Many healthcare regulatory bodies, including FDA and EMA, are advocating for AI systems with interpretable decision-making processes, driving innovation in XAI-powered diagnostic tools. By incorporating explainability and interpretability into AI models, clinicians can better understand how AI diagnoses cancer, leading to more informed decision-making and improved patient trust (Akinade *et al.*, 2021; Elujide *et al.*, 2021).

AI is paving the way for precision oncology, where treatment plans are tailored to individual patients based on their genetic, molecular, and clinical profiles. Future AI-driven innovations in this field include; AI models will integrate genomic, transcriptomic, proteomic, and metabolomic data to predict patient-specific treatment responses. AI-powered models will help forecast how tumors will respond to various therapies, optimizing chemotherapy, immunotherapy,

and targeted therapy regimens. AI will facilitate real-time treatment adjustments based on tumor evolution, improving long-term patient survival rates (Hassan *et al.*, 2021). These advancements will transform cancer care from a one-size-fits-all approach to a highly individualized treatment paradigm, improving efficacy and reducing unnecessary treatments.

One of the biggest challenges in AI-driven cancer diagnosis is data privacy and security, as patient data is highly sensitive and protected under regulations such as HIPAA and GDPR. Federated learning (FL) is emerging as a privacy-preserving AI approach that allows multiple institutions to train AI models collaboratively without sharing raw patient data. Instead of transferring patient data, FL trains AI models locally at different hospitals and shares only model updates, protecting patient privacy (Ajayi and Akerele, 2021). By leveraging FL, AI models can learn from diverse datasets across different hospitals, improving generalizability and robustness. FL aligns with data protection regulations, enabling global AI research without compromising patient confidentiality. The widespread adoption of federated learning will accelerate AI-driven cancer diagnostics while maintaining ethical and legal compliance, fostering trust in AI-powered healthcare (Tomassoni *et al.*, 2013).




Figure 3: Future Directions and Innovations in AI for Cancer Diagnosis

AI is increasingly being utilized for predictive analytics, which enables early cancer detection, risk assessment, and proactive intervention strategies (Tayebati *et al.*, 2013). Future AI models will incorporate AI will analyze long-term patient data from electronic health records (EHRs), wearable sensors, and imaging scans to detect subtle

precancerous changes before symptoms appear. AI-driven risk models will classify patients based on genetic predisposition, lifestyle factors, and clinical history, enabling targeted screening programs. AI-integrated biosensors and wearable devices will provide continuous health tracking, enabling early warning systems for high-risk patients. By shifting cancer detection from a reactive to a proactive approach, predictive AI will enhance early intervention efforts, reducing mortality rates and improving long-term patient outcomes.

AI is not intended to replace oncologists and radiologists but to serve as an augmentative tool that enhances clinical decision-making (Nasuti *et al.*, 2008). Future innovations in AI-human collaboration will focus on; Decision support systems (DSS), AI-driven DSS will assist clinicians by analyzing complex medical data, providing second opinions, and flagging potential diagnostic errors. Combining human expertise with AI insights will improve diagnostic accuracy and reduce false positives/negatives. Future AI tools will feature natural language processing (NLP) interfaces, allowing doctors to query AI models in plain language, improving usability and accessibility. AI-driven simulation platforms will help train oncologists and radiologists by mimicking real-world diagnostic scenarios, improving skill development. By promoting a synergistic relationship between AI and healthcare professionals, AI-human collaboration will enhance diagnostic confidence, reduce workload, and improve patient care. The future of AI in cancer diagnosis is poised for transformative advancements (Tayebati *et al.*, 2013). Explainable AI, personalized oncology, federated learning, predictive analytics, and AI-human collaboration will drive more accurate, ethical, and accessible cancer diagnostics. These innovations will enable earlier detection, improved treatment personalization, and enhanced clinical decision-making, ultimately leading to better patient outcomes and reduced cancer mortality rates (Tomassoni *et al.*, 2012; Alli and Dada, 2021). Continued research, regulatory alignment, and interdisciplinary collaboration will be crucial in realizing the full potential of AI-driven cancer diagnostics in the coming years.

CONCLUSION

Artificial intelligence (AI) has emerged as a transformative force in cancer diagnosis, offering advancements in medical imaging, histopathology, and genomic analysis. Key findings from this review highlight how AI-driven approaches, particularly machine learning (ML) and deep learning (DL), have enhanced diagnostic accuracy, efficiency, and early detection rates. Technologies such as Convolutional Neural Networks (CNNs), transformer-based models, and radiomics have demonstrated superior performance in analyzing complex medical data, while AI-integrated electronic health records (EHRs) and multi-omics data have improved personalized treatment strategies. Furthermore, federated learning presents a promising solution for privacy-preserving AI training in healthcare.

The potential impact of AI in cancer diagnosis is profound. By reducing diagnostic errors, enabling early detection, and streamlining workflows, AI can significantly improve patient outcomes and survival rates. AI-powered predictive analytics and risk stratification models enhance proactive screening efforts, while AI-driven personalized treatment planning fosters precision oncology, ensuring tailored therapeutic interventions. However, interpretability, regulatory compliance, and data standardization remain critical challenges that must be addressed to ensure AI's widespread adoption in clinical settings.

Future research should focus on developing explainable AI (XAI) models to enhance transparency and clinician trust. Additionally, efforts should be directed toward AI-human collaboration frameworks, where AI serves as a decision-support tool rather than a replacement for medical professionals. Standardized datasets and ethical AI frameworks should be prioritized to ensure fairness, reproducibility, and regulatory alignment. AI is reshaping oncology by enhancing diagnostic precision, optimizing workflows, and advancing personalized medicine. As AI technologies evolve, a collaborative, interdisciplinary approach will be essential to maximize their potential while ensuring ethical, reliable, and equitable implementation in cancer diagnosis and treatment.

REFERENCES

- [1] Adegoke, S.A., Oladimeji, O.I., Akinlosotu, M.A., Akinwumi, A.I. and Matthew, K.A., 2022. HemoTypeSC point-of-care testing shows high sensitivity with alkaline cellulose acetate hemoglobin electrophoresis for screening hemoglobin SS and SC genotypes. *Hematology, Transfusion and Cell Therapy*, 44(3), pp.341-345.
- [2] Adelodun, A.M., Adekanmi, A.J., Roberts, A. and Adeyinka, A.O., 2018. Effect of asymptomatic malaria parasitemia on the uterine and umbilical artery blood flow impedance in third-trimester singleton Southwestern Nigerian pregnant women. *Tropical Journal of Obstetrics and Gynaecology*, 35(3), pp.333-341.
- [3] Adepoju, A.H., Austin-Gabriel, B.L.E.S.S.I.N.G., Eweje, A.D.E.O.L.U.W.A. and Collins, A.N.U.O.L.U.W.A.P.O., 2022. Framework for automating multi-team workflows to maximize operational efficiency and minimize redundant data handling. *IRE Journals*, 5(9), pp.663-664.
- [4] Adepoju, A.H., Austin-Gabriel, B.L.E.S.S.I.N.G., Hamza, O.L.A.D.I.M.E.J.I. and Collins, A.N.U.O.L.U.W.A.P.O., 2022. Advancing monitoring and alert systems: A proactive approach to improving reliability in complex data ecosystems. *IRE Journals*, 5(11), pp.281-282.
- [5] Adepoju, P.A., Adeola, S., Ige, B., Chukwuemeka, C., Oladipupo Amoo, O. and Adeoye, N., 2022. Reimagining multi-cloud interoperability: A conceptual framework for seamless integration and security across cloud platforms. *Open Access Research Journal of Science and Technology*, 4(1), pp.071-082.
- [6] Adepoju, P.A., Austin-Gabriel, B., Ige, A.B., Hussain, N.Y., Amoo, O.O. and Afolabi, A.I., 2022. Machine learning innovations for enhancing quantum-resistant cryptographic protocols in secure communication. *Open Access Research Journal of Multidisciplinary Studies*, 4(1), pp.131-139.
- [7] Adepoju, P.A., Austin-Gabriel, B., Ige, A.B., Hussain, N.Y., Amoo, O.O. and Afolabi, A.I., 2022. Machine learning innovations for

- enhancing quantum-resistant cryptographic protocols in secure communication. *Open Access Research Journal of Multidisciplinary Studies*, 4(1), pp.131-139.
- [8] Adepoju, P.A., Oladosu, S.A., Ige, A.B., Ike, C.C., Amoo, O.O. and Afolabi, A.I., 2022. Next-generation network security: Conceptualizing a unified, AI-powered security architecture for cloud-native and on-premise environments. *International Journal of Science and Technology Research Archive*, 3(2), pp.270-280.
- [9] Adewoyin, M.A., 2021. Developing frameworks for managing low-carbon energy transitions: overcoming barriers to implementation in the oil and gas industry.
- [10] Adewoyin, M.A., 2022. Advances in risk-based inspection technologies: Mitigating asset integrity challenges in aging oil and gas infrastructure.
- [11] Agho, G., Ezeh, M.O., Isong, M., Iwe, D. and Oluseyi, K.A., 2021. Sustainable pore pressure prediction and its impact on geo-mechanical modelling for enhanced drilling operations. *World Journal of Advanced Research and Reviews*, 12(1), pp.540-557.
- [12] Ajayi, A. and Akerele, J.I., 2021. A high-impact data-driven decisionmaking model for integrating cutting-edge cybersecurity strategies into public policy, governance, and organizational frameworks. *International Journal of Multidisciplinary Research and Growth Evaluation*, 2(1), pp.623-637.
- [13] Ajayi, A. and Akerele, J.I., 2022. A practical framework for advancing cybersecurity, artificial intelligence, and technological ecosystems to support regional economic development and innovation. *International Journal of Multidisciplinary Research and Growth Evaluation*, 3(1), pp.700-13.
- [14] Ajayi, A. and Akerele, J.I., 2022. A scalable and impactful model for harnessing artificial intelligence and cybersecurity to revolutionize workforce development and empower marginalized youth. *International Journal of Multidisciplinary Research and Growth Evaluation*, 3(1), pp.714-719.
- [15] Akinade, A.O., Adepoju, P.A., Ige, A.B., Afolabi, A.I. and Amoo, O.O., 2022. Advancing segment routing technology: A new model for scalable and low-latency IP/MPLS backbone optimization. *Open Access Research Journal of Science and Technology*, 5(2), pp.77-95.
- [16] Akinade, A.O., Adepoju, P.A., Ige, A.B., Afolabi, A.I. and Amoo, O.O., 2021. A conceptual model for network security automation: Leveraging AI-driven frameworks to enhance multi-vendor infrastructure resilience. *International Journal of Science and Technology Research Archive*, 1(1), pp.39-59.
- [17] Alli, O.I. and Dada, S.A., 2021. Innovative Models for Tobacco Dependency Treatment: A Review of Advances in Integrated Care Approaches in High-Income Healthcare Systems. *IRE Journals*, 5(6), pp.273-282.
- [18] Atta, J.A., Al Zoubi, M.A.M., Temedie-Asogwa, T. and Amafah, J., 2021. Comparing the Cost-Effectiveness of Pharmaceutical vs. Non-Pharmaceutical Interventions for Diabetes Management.
- [19] Austin-Gabriel, B., Hussain, N.Y., Ige, A.B., Adepoju, P.A., Amoo, O.O. and Afolabi, A.I., 2021. Advancing zero trust architecture with AI and data science for enterprise cybersecurity frameworks. *Open Access Research Journal of Engineering and Technology*, 1(01), pp.047-055.
- [20] Bidemi, A.I., Oyindamola, F.O., Odum, I., Stanley, O.E., Atta, J.A., Olatomide, A.M., Nnamdi, N.C., Amafah, J. and Helen, O.O., 2021. Challenges Facing Menstruating Adolescents: A Reproductive Health Approach. *Journal of Adolescent Health*, 68(5), pp.1-10.
- [21] Bristol-Alagbariya, B., Ayanponle, O.L. and Ogedengbe, D.E., 2022. Strategic frameworks for contract management excellence in global energy HR operations. *GSC Advanced Research and Reviews*, 11(3), pp.150-157.
- [22] Bristol-Alagbariya, B., Ayanponle, O.L. and Ogedengbe, D.E., 2022. Developing and implementing advanced performance management systems for enhanced organizational productivity. *World Journal of Advanced Science and Technology*, 2(1), pp.39-46.

- [23] Charles, O.I., Hamza, O., Eweje, A., Collins, A., Babatunde, G.O. and Ubamadu, B.C., 2022. International Journal of Social Science Exceptional Research.
- [24] Collins, A., Hamza, O. and Eweje, A., 2022. CI/CD pipelines and BI tools for automating cloud migration in telecom core networks: A conceptual framework. *IRE Journals*, 5(10), pp.323-324.
- [25] Collins, A., Hamza, O. and Eweje, A., 2022. Revolutionizing edge computing in 5G networks through Kubernetes and DevOps practices. *IRE Journals*, 5(7), pp.462-463.
- [26] Dienagha, I.N., Onyeke, F.O., Digitemie, W.N. and Adekunle, M., 2021. Strategic reviews of greenfield gas projects in Africa: Lessons learned for expanding regional energy infrastructure and security.
- [27] Dirlikov, E., Jahun, I., Odafe, S.F., Obinna, O., Onyenuobi, C., Ifunanya, M., Efuntoye, T.A., Tingir, N., Ene, U., Fagbemi, A. and Meribe, C., 2021. Section navigation rapid scale-up of an antiretroviral therapy program before and during the COVID-19 pandemic-nine states, Nigeria, March 31, 2019-September 30, 2020.
- [28] Egbuonu, A.C.C., Alaabo, P.O., Njoku, C.J., Oriaku, C.E. and Emeonye, C., 2022. The Role of l-arginine in prevention of testicular function toxicity induced by monosodium glutamate burden in Wistar rats: <https://doi.org/10.51412/psnnjp.2022.25>. *The Nigerian Journal of Pharmacy*, 56(2).
- [29] Elujide, I., Fashoto, S.G., Fashoto, B., Mbunge, E., Folorunso, S.O. and Olamijuwon, J.O., 2021. Informatics in Medicine Unlocked.
- [30] Elujide, I., Fashoto, S.G., Fashoto, B., Mbunge, E., Folorunso, S.O. and Olamijuwon, J.O., 2021. Application of deep and machine learning techniques for multi-label classification performance on psychotic disorder diseases. *Informatics in Medicine Unlocked*, 23, p.100545.
- [31] Gbadegesin, J.O., Adekanmi, A.J., Akinmoladun, J.A. and Adedun, A.M., 2022. Determination of Fetal gestational age in singleton pregnancies: Accuracy of ultrasonographic placenta thickness and volume at a Nigerian tertiary Hospital. *African Journal of Biomedical Research*, 25(2), pp.113-119.
- [32] Govender, P., Fashoto, S.G., Maharaj, L., Adeleke, M.A., Mbunge, E., Olamijuwon, J., Akinnuwesi, B. and Okpeku, M., 2022. The application of machine learning to predict genetic relatedness using human mtDNA hypervariable region I sequences. *Plos one*, 17(2), p.e0263790.
- [33] Hamza, O., Collins, A. and Eweje, A., 2022. A comparative analysis of ETL techniques in telecom and financial data migration projects: Advancing best practices. *ICONIC Research and Engineering Journals*, 6(1), p.737.
- [34] Hassan, Y.G., Collins, A., Babatunde, G.O., Alabi, A.A. and Mustapha, S.D., 2021. AI-driven intrusion detection and threat modeling to prevent unauthorized access in smart manufacturing networks. *Artificial intelligence (AI)*, p.16.
- [35] Hussain, N.Y., Austin-Gabriel, B., Ige, A.B., Adepoju, P.A., Amoo, O.O. and Afolabi, A.I., 2021. AI-driven predictive analytics for proactive security and optimization in critical infrastructure systems. *Open Access Research Journal of Science and Technology*, 2(02), pp.006-015.
- [36] Ige, A.B., Austin-Gabriel, B., Hussain, N.Y., Adepoju, P.A., Amoo, O.O. and Afolabi, A.I., 2022. Developing multimodal AI systems for comprehensive threat detection and geospatial risk mitigation. *Open Access Research Journal of Science and Technology*, 6(01), pp.093-101.
- [37] Ike, C.C., Ige, A.B., Oladosu, S.A., Adepoju, P.A., Amoo, O.O. and Afolabi, A.I., 2021. Redefining zero trust architecture in cloud networks: A conceptual shift towards granular, dynamic access control and policy enforcement. *Magna Scientia Advanced Research and Reviews*, 2(1), pp.074-086.
- [38] Jahun, I., Dirlikov, E., Odafe, S., Yakubu, A., Boyd, A.T., Bachanas, P., Nzelu, C., Aliyu, G., Ellerbrock, T., Swaminathan, M. and CDC Nigeria ART Surge Team, 2021. Ensuring optimal community HIV testing services in Nigeria using an enhanced community case-finding package (ECCP), October 2019–March

- 2020: acceleration to HIV epidemic control. *HIV/AIDS-Research and Palliative Care*, pp.839-850.
- [39] Jahun, I., Said, I., El-Imam, I., Ehoche, A., Dalhatu, I., Yakubu, A., Greby, S., Bronson, M., Brown, K., Bamidele, M. and Boyd, A.T., 2021. Optimizing community linkage to care and antiretroviral therapy Initiation: Lessons from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIS) and their adaptation in Nigeria ART Surge. *PLoS One*, 16(9), p.e0257476.
- [40] Kuo, Y.M., Nwankwo, E.I., Nussbaum, R.L., Rogers, J. and Maccacchini, M.L., 2019. Translational inhibition of α -synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. *American journal of neurodegenerative disease*, 8(1), p.1.
- [41] Matthew, A., Opia, F.N., Matthew, K.A., Kumolu, A.F. and Matthew, T.F., 2021. Cancer Care Management in the COVID-19 Era: Challenges and adaptations in the global south. *Cancer*, 2(6).
- [42] Matthew, K.A., AKINWALE, F.M., OPIA, F.N. and Adenike, A., 2021. The Relationship between oral Contraceptive Use, Mammographic Breast Density, and Breast Cancer Risk.
- [43] Matthew, K.A., Opia, F.N., Matthew, A., Kumolu, A.F. and Matthew, T.F., 2022. Achieving Personalized Oncology Care: Insights and Challenges in Sub-Saharan Africa.
- [44] Nasuti, C., Falcioni, M.L., Nwankwo, I.E., Cantalamessa, F. and Gabbianelli, R., 2008. Effect of permethrin plus antioxidants on locomotor activity and striatum in adolescent rats. *Toxicology*, 251(1-3), pp.45-50.
- [45] Nwaozomudoh, M.O., Odio, P.E., Kokogho, E., Olorunfemi, T.A., Adeniji, I.E. and Sobowale, A., 2021. Developing a conceptual framework for enhancing interbank currency operation accuracy in Nigeria's banking sector. *International Journal of Multidisciplinary Research and Growth Evaluation*, 2(1), pp.481-494.
- [46] Odio, P.E., Kokogho, E., Olorunfemi, T.A., Nwaozomudoh, M.O., Adeniji, I.E. and Sobowale, A., 2021. Innovative financial solutions: A conceptual framework for expanding SME portfolios in Nigeria's banking sector. *International Journal of Multidisciplinary Research and Growth Evaluation*, 2(1), pp.495-507.
- [47] Oladosu, S.A., Ike, C.C., Adepoju, P.A., Afolabi, A.I., Ige, A.B. and Amoo, O.O., 2021. The future of SD-WAN: A conceptual evolution from traditional WAN to autonomous, self-healing network systems. *Magna Scientia Advanced Research and Reviews*.
- [48] Olamijuwon, O.J., 2020. *Real-time Vision-based Driver Alertness Monitoring using Deep Neural Network Architectures* (Master's thesis, University of the Witwatersrand, Johannesburg (South Africa)).
- [49] Oluokun, O.A., 2021. *Design of a Power System with Significant Mass and Volume Reductions, Increased Efficiency, and Capability for Space Station Operations Using Optimization Approaches* (Doctoral dissertation, McNeese State University).
- [50] Opia, F.N., MATTHEW, K.A. and MATTHEW, T.F., 2022. Leveraging Algorithmic and Machine Learning Technologies for Breast Cancer Management in Sub-Saharan Africa.
- [51] Oyedokun, O.O., 2019. *Green human resource management practices and its effect on the sustainable competitive edge in the Nigerian manufacturing industry (Dangote)* (Doctoral dissertation, Dublin Business School).
- [52] Ozobu, C.O., Adikwu, F.E., Odujobi, O., Onyekwe, F.O. and Nwulu, E.O., 2022. A Conceptual Model for Reducing Occupational Exposure Risks in High-Risk Manufacturing and Petrochemical Industries through Industrial Hygiene Practices.
- [53] Tayebati, Khosrow S., Ejike Nwankwo, I. and Amenta, F., 2013. Intranasal drug delivery to the central nervous system: present status and future outlook. *Current pharmaceutical design*, 19(3), pp.510-526.
- [54] Tayebati, Khosrow S., Tomassoni, D., Ejike Nwankwo, I., Di Stefano, A., Sozio, P., Serafina Cerasa, L. and Amenta, F., 2013. Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain. *CNS & Neurological Disorders-Drug Targets (Formerly*

Current Drug Targets-CNS & Neurological Disorders), 12(1), pp.94-103.

- [55] Tomassoni, D., Amenta, F., Amantini, C., Farfariello, V., Di Cesare Mannelli, L., Nwankwo, I.E., Marini, C. and Tayebati, S.K., 2013. Brain activity of thioctic acid enantiomers: in vitro and in vivo studies in an animal model of cerebrovascular injury. *International Journal of Molecular Sciences*, 14(3), pp.4580-4595.
- [56] Tomassoni, D., Amenta, F., Di Cesare Mannelli, L., Ghelardini, C., Nwankwo, I.E., Pacini, A. and Tayebati, S.K., 2013. Neuroprotective activity of thioctic acid in central nervous system lesions consequent to peripheral nerve injury. *BioMed Research International*, 2013(1), p.985093.
- [57] Tomassoni, D., Catalani, A., Cinque, C., Antonietta Di Tullio, M., Khosrow Tayebati, S., Cadoni, A., Ejike Nwankwo, I., Traini, E. and Amenta, F., 2012. Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats. *Current Alzheimer Research*, 9(1), pp.120-127.
- [58] Tomassoni, D., Nwankwo, I.E., Gabrielli, M.G., Bhatt, S., Muhammad, A.B., Lokhandwala, M.F., Tayebati, S.K. and Amenta, F., 2013. Astrogliosis in the brain of obese Zucker rat: a model of metabolic syndrome. *Neuroscience letters*, 543, pp.136-141.